Topical Diacerein in Psoriasis Vulgaris
Condition(s) studied
Investigational drug(s) / intervention(s)
Diacerein: Topical diacerein cream 1% will be applied to affected skin areas twice daily for a treatment duration of two months.
Placebo: A matching placebo topical formulation will be applied to affected skin areas twice daily for a treatment duration of two months.
Study summary
The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the placebo group.
Participants will:
Be assigned to receive topical diacerein 1% or placebo twice daily for a treatment period of 2 months.
Attend follow-up visits at Weeks 2, 4, 6, and 8. Undergo an additional evaluation one month after treatment cessation.
Eligibility
Primary outcome measure(s)
- Proportion of Participants Achieving PASI 75 — Week 8
The proportion of participants who achieve at least a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI 75), comparing the topical diacerein group with the placebo group.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Kasr Al-Ainy Psoriasis Unit | Cairo | Egypt |
More Cairo University trials in Egypt
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07352306 on ClinicalTrials.gov ↗ ← All trials in Egypt